Friday, February 06, 2015 6:21:14 PM
The median analyst price target on GILD is still $118 even with today's CS change:
https://www.flashratings.com/stocks/1046-GILD?in=true
It wasn't the Suisse downgrade that pushed GILD in the red today as the financial media on CNBC was implying this afternoon.
That downgrade was published before the market open and GILD dipped and ripped holding up until well after lunch. Then the algos hit the sell button again on all the Index Funds after news of S&P Greece downgrade broke.
Overlaying the SPY and IBB intraday charts with the GILD intraday one min tells the real story. These broad market auto selloffs are the best times to buy, imo.
Recent GILD News
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 04/30/2024 08:05:00 PM
- FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV • Business Wire • 04/26/2024 12:00:00 PM
- Exxon Mobil Net Profit Drops 28% to $8.22 Billion, Atlassian Surprises with Revenue Boost and Co-CEO Exit, and More in Earnings • IH Market News • 04/26/2024 11:47:51 AM
- Gilead Sciences Announces First Quarter 2024 Financial Results • Business Wire • 04/25/2024 08:02:00 PM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024 • Business Wire • 04/08/2024 08:05:00 PM
- FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six • Business Wire • 03/28/2024 12:30:00 PM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program • Business Wire • 03/28/2024 11:00:00 AM
- Gilead Sciences Announces Completion of Acquisition of CymaBay • Business Wire • 03/22/2024 01:18:00 PM
- Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant • Business Wire • 03/18/2024 11:29:00 PM
- Form SC TO-T/A - Tender offer statement by Third Party: [Amend] • Edgar (US Regulatory) • 03/11/2024 12:34:07 PM
- Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer • Business Wire • 03/11/2024 12:24:00 PM
- Biktarvy® Demonstrates High Rates of Viral Suppression in People With HIV and Comorbidities • Business Wire • 03/06/2024 09:30:00 PM
- Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 • Business Wire • 03/06/2024 03:25:00 PM
- Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers • Business Wire • 03/06/2024 01:00:00 PM
- New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19 • Business Wire • 03/05/2024 09:35:00 PM
- Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health • Business Wire • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 11:35:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:49:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 09:38:50 PM
- Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S. • Business Wire • 02/27/2024 03:00:00 PM
- U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance • Business Wire • 02/26/2024 09:05:00 PM
- Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024 • Business Wire • 02/26/2024 01:30:00 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 02/23/2024 11:09:33 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM